The ALL-HEART study is the first large, randomised trial assessing allopurinol in patients with ischaemic heart disease. In this touchCARDIO interview, we speak with Professor Isla Mackenzie (University of Dundee, Dundee, Scotland) to discuss the rationale for the ALL-HEART study, its findings and the future of allopurinol in ischaemic heart disease. Â
The abstract entitled ‘ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What is the rationale for investigating whether allopurinol improves cardiovascular outcomes in patients with ischaemic heart disease? (0:19)
- What were the aims and design of the ALL-HEART study? (1:24)
- What were the primary and secondary outcome measures and how well were they achieved? (2:01)
- Why do you think these findings failed to reach statistical significance, and what is the future for allopurinol in this indication? (3:06)
Disclosures: Isla Mackenzie is a consultant for Amgen and AstraZeneca and has received grant or research support from British Heart Foundation, EMA, HDR UK, IMI, Menarini, NIHR HTA and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Disease here
